Crestor 5 mg

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Crestor 5 mg

Quick Facts

Property Description
Active ingredient Rosuvastatin calcium
Form Film-coated tablet
Pharmacological class HMG-CoA reductase inhibitor (Statin)
Common use Lipid-lowering agent for hypercholesterolemia
Origin Synthetic compound

What Type of Medicine is Crestor 5 mg?

Crestor 5 mg is a synthetic prescription-only medicine centered on the active substance Rosuvastatin calcium. It belongs to the pharmacological class known as HMG-CoA reductase inhibitors, widely categorized as statins, which are foundational agents for managing lipid disorders. Rosuvastatin is notable within this group as a potent compound, distinguished by its high degree of liver selectivity and its long duration of action compared to many older statin compounds. This differentiation is recognized in medical consensus for providing effective cholesterol control.

This classification highlights the drug's primary therapeutic role as a potent lipid-lowering agent. Its core function is to reduce elevated total cholesterol and the harmful low-density lipoprotein cholesterol (LDL-C) in the bloodstream, a key strategy for overall cardiovascular protection and mitigating the long-term risk factors associated with atherosclerotic disease. The robust efficacy of statins has been consistently documented across major clinical guidelines, establishing them as primary interventions for reducing major adverse cardiovascular events.


Composition and General Purpose of the Crestor 5 mg Tablet

The Crestor 5 mg preparation is provided as a film-coated tablet designed exclusively for oral administration. The product is a single-ingredient formulation, featuring Rosuvastatin calcium salt as the sole active component, combined with necessary inactive excipients. The specific 5 mg dose strength is typically indicated for patients starting therapy or those requiring moderate LDL-C reduction, providing physicians with titration flexibility.

The general purpose of the Rosuvastatin molecule is to manage hypercholesterolemia and various forms of dyslipidemia by inhibiting the vital enzyme in the cholesterol synthesis pathway. This action supports the long-term maintenance of healthier blood lipid profiles, a fundamental component of systematic risk reduction.

Regulatory References

  1. Rosuvastatin - StatPearls

What side effects are possible with Crestor 5 mg?

Possible side effects and safety information

The safety profile of rosuvastatin, the active ingredient in Crestor 5 mg, is classified by frequency and the physiological systems affected, based on authoritative government regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized according to their estimated rate of occurrence:

Frequency Examples of Documented Adverse Reactions
Common (ge 1/100 to < 1/10) Headache, dizziness, constipation, nausea, abdominal pain, myalgia (muscle pain), and asthenia (weakness).
Uncommon (ge 1/1,000 to < 1/100) Hypersensitivity reactions (including angioedema), pruritus (itching), rash, and urticaria (hives).
Rare (ge 1/10,000 to < 1/1,000) Pancreatitis, increased transaminases (liver enzymes), myopathy (muscle disease), and rhabdomyolysis.

Serious adverse reactions officially highlighted in regulatory labeling include rhabdomyolysis, hepatitis, and jaundice. These are rare but clinically significant events involving the musculoskeletal and hepatobiliary systems.

Safety-Related Constraints and Population Notes

The official labeling notes specific safety constraints. The medicine is contraindicated in individuals with active liver disease or unexplained, persistent elevations of serum transaminases exceeding three times the upper limit of normal. Safety information also documents increased systemic exposure in patients with renal impairment and individuals of Asian ethnicity.

Dose-Related Safety Patterns

The risk of myopathy, which is a condition affecting the muscle tissue, is explicitly documented as dose-dependent. Furthermore, effects on the renal system, such as proteinuria and haematuria, have been primarily observed in patients receiving higher doses and are typically transient.

Overdose and Emergency Response

Overdose and when to seek help

The management of Crestor (rosuvastatin) overexposure is strictly defined by regulatory guidance as symptomatic and supportive. The officially documented concern following overexposure is the potential for developing rhabdomyolysis, a severe breakdown of muscle tissue, which can subsequently lead to acute kidney injury.

Documented Manifestations and Emergency Action

Feature Official Regulatory Statement
Documented Presentations Overexposure may present with myopathy (muscle disease) and signs of rhabdomyolysis. Laboratory findings include marked elevations in Creatine Kinase (CK) levels and signs of renal and hepatic toxicity (e.g., proteinuria and elevated serum transaminases).
Emergency Response Individuals must seek immediate medical attention or get medical help right away if overexposure is known or suspected. The medicine must be immediately discontinued.

Supportive Treatment and Specific Antidote

Regulatory documents state that no specific antidote is known for rosuvastatin. Management focuses on providing necessary symptomatic and supportive treatment, with mandated monitoring of liver function, kidney function, and Creatine Kinase levels to manage the risk of severe complications. Furthermore, hemodialysis is not expected to be beneficial due to the drug's high level of plasma protein binding, reinforcing the need for immediate professional medical intervention upon suspicion of overdose.

Therapeutic Uses of Crestor 5 mg

What Crestor 5 mg Treats: Main Uses and Benefits

Crestor is commonly used to manage dyslipidemia—a category of conditions involving abnormal blood fat levels, including primary hypercholesterolemia and mixed dyslipidemia. It is relevant for easing groups of risk factors defined by elevated total cholesterol and harmful LDL-C (low-density lipoprotein cholesterol), which contributes to easing the overall symptom load. The therapeutic benefit provides supportive relief by managing the lipid profile.


The medicine is generally applied in high-risk clinical scenarios for the management of major adverse cardiovascular events (MACE). This is relevant for patients diagnosed with established atherosclerotic disease (secondary prevention) and for adults identified as being at increased risk due to multiple factors. The key patient-oriented benefit supports the easing of cardiovascular risk factors, which helps support functional stability and manage symptoms that interfere with daily functioning. It is applied in situations requiring long-term supportive management to ease the progression of atherosclerosis.

Quick Fact: Relief for Systemic Imbalance
Primary Benefit Supports the easing of systemic imbalance related to cardiovascular risk factors.
Typical Context Used as an adjunct to diet and exercise for chronic, systemic lipid imbalance.
Key Use Case Supports the management of conditions presenting with systemic imbalance.

Regulatory References

  1. DailyMed (NIH) Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Crestor 5 mg — Official Regulatory Information

The eligibility profile for Crestor (rosuvastatin) is strictly defined by government regulatory documents, focusing on absolute exclusions and conditional use in specific populations. Use is broadly allowed for adult patients and older adults but is constrained by physiological status and comorbidities.


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is contraindicated: Individuals with active liver disease or unexplained persistent elevations of liver enzymes.
Women who are pregnant, may become pregnant, or are breastfeeding.
Patients with known hypersensitivity to rosuvastatin or any component.
Age-related eligibility rules: Use is generally not established for children under 7 years of age for any indication.
Pediatric use (7 to 18 years) is restricted to patients with Familial Hypercholesterolemia (HeFH or HoFH).
Condition-specific eligibility rules: Patients with severe renal impairment (creatinine clearance less than 30 mL/min) must not use certain high doses.
Asian patients and those with moderate renal impairment (CrCl < 60 mL/min) are subject to conditional restriction and lower starting dose recommendations.

Connection to the overall eligibility profile

Regulatory documents precisely define who can and cannot use rosuvastatin by establishing categories of absolute contraindication based on physiological status (pregnancy, lactation) and comorbidity (active liver disease). Eligibility in pediatric populations is restricted solely to specific genetic conditions, formally limiting who may receive the medicine based on age and diagnosis.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Rosuvastatin is structured around specific co-administered substances that may alter the drug’s systemic exposure or enhance safety risks.

Interacting Substances and Constraints

Medicinal product categories with documented interactions: Lipid-Modifying Agents (e.g., Fibrates, Niacin ge 1 g/day), Immunosuppressants (Cyclosporine), Antivirals, Antacids, and Coumarin anticoagulants.

Mechanistic basis of interactions: Exposure-modifying interactions are predominantly mediated by the inhibition of OATP1B1 and BCRP transporter proteins, which leads to an increase in rosuvastatin plasma concentrations.

Interaction-related restrictions:

Interacting Substance Official Constraint (Due to Increased Exposure)
Cyclosporine Rosuvastatin dose must not exceed 5 mg once daily.
Gemfibrozil Avoid concomitant use; if unavoidable, dose must not exceed 10 mg once daily.
Antivirals (select combinations) Rosuvastatin dose must not exceed 10 mg once daily.

Timing-based interaction rules: The co-administration of aluminum and magnesium hydroxide antacids requires Rosuvastatin to be administered at least 2 hours after the antacid to mitigate a documented reduction in rosuvastatin absorption.

Population-specific notes: Regulatory documents note that Asian patients exhibit an approximate 2-fold increase in median systemic exposure, resulting in a caution to consider a 5 mg starting dose in this population.

Mechanism of Action

Targeted Inhibition of Cholesterol Production

This domain covers the primary molecular action of Rosuvastatin: it acts as a competitive inhibitor of the enzyme HMG-CoA Reductase inside liver cells (hepatocytes). This mechanism interrupts the mevalonate pathway, the body's main route for manufacturing its own cholesterol, resulting in a reduction in the synthesis of cholesterol within the liver.


⏫ Feedback-Driven Clearance of Plasma LDL-C

The resulting lack of internal cholesterol synthesis triggers a compensatory mechanistic cascade. The liver cells upregulate, or dramatically increase, the number of LDL Receptors on their surface. This action enhances the liver's capacity for lipid clearance from the bloodstream, pulling LDL-C and VLDL particles directly from the circulation, resulting in a physiological consequence of reduced circulating cholesterol levels.


️ Modulation of Vascular and Inflammatory Systems

Beyond its primary metabolic role, the drug engages mechanisms that affect the vasculature. These pleiotropic effects involve modulating pathways that affect the function of the blood vessel lining (endothelium) and reduce markers of systemic low-grade inflammation, such as C-Reactive Protein (CRP). This activity within vascular walls and inflammatory systems acts concurrently with the lipid-clearing mechanism.

Dosage and Administration Information

Instruction Map: How to use Crestor 5 mg — Official Administration Guidelines

The use of rosuvastatin tablets is based on a standardized, high-level protocol. The film-coated tablet is designed for oral administration and must be swallowed whole without being crushed or chewed. The medicine is taken once daily and offers flexibility as it can be administered at any time of the day, with or without food.


Administration Scope

Instruction Detail
Route of administration Oral, as a single, film-coated tablet.
Dosing schedule (Adults) Dosage ranges from 5 mg to 40 mg once daily. Titration to a higher dose, if required, should occur at intervals of 4 weeks or more.
Timing in relation to meals May be taken with or without food at any time of day.
Missed-dose rule If a dose is missed, patients should not take an extra dose; treatment should simply resume with the next scheduled dose.
Special procedural conditions The standard adult starting dose is 10 mg. A 5 mg starting dose is recommended for patients of Asian descent and for those with severe renal impairment. The 40 mg maximum daily dose is reserved for specific patient cases.

Connection to the overall use protocol

This protocol defines rosuvastatin as a long-term, daily oral medication that uses specific titration rules and population-based starting doses to standardize its introduction into therapy. The guidance simplifies daily use by confirming the independence of administration from meal timing and scheduling, ensuring the proper framework for consistent dosing.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Crestor 5 mg

Evidence for Managing Elevated Lipids (Dyslipidemia)

Research examined rosuvastatin in adults with conditions marked by elevated blood lipid levels, such as primary hypercholesterolemia. Studies monitored outcomes related to lipid levels, specifically focusing on the levels of fats in the bloodstream. These investigations primarily used short-term randomized controlled trials (RCTs) and comparative studies, where different doses of rosuvastatin was evaluated in adults against a placebo or other active agents.

The main focus of these studies was to monitor shifts in key lipid biomarkers over short observation periods. Furthermore, some intermediate-term dedicated imaging research, with follow-up durations extending up to two years, studies monitored surrogate markers like changes in the size of arterial plaque, known as atheroma volume.

Evidence for Reducing Cardiovascular Event Risk

The use of rosuvastatin was evaluated in large-scale, international clinical research to assess how the agent was associated with the frequency of major adverse cardiovascular events (MACE), such as heart attack and stroke. This research explored both primary prevention (adults with specific risk factors but no prior event) and secondary prevention (patients who have already experienced such an event).

Researchers conducted a large, placebo-controlled RCT that included high-risk adults. This trial monitored the occurrence of a composite MACE endpoint. Meta-analyses, which consolidate data from multiple trials, data show patterns related to event frequency across diverse high-risk populations. The primary prevention RCT was concluded earlier than planned, meaning the full extent of long-term effects are not fully established beyond the median follow-up duration.

Research Focus on Familial Hypercholesterolemia

Research explored rosuvastatin in children and adolescents diagnosed with genetic forms of high cholesterol. Long-term parameters related to safety were monitored through open-label extension studies lasting up to two years. These trials monitored outcomes related to specific lipid biomarkers in these younger populations, while also exploring primary safety indicators related to normal development, including tracking physical growth and sexual maturation.

Areas of Research Uncertainty and Study Gaps

The evidence highlights what is known—and what is still uncertain—about this medicine. Comparative evidence is not available for certain specific dose-to-dose comparisons with all other medicines in this class. Subgroup findings are uncertain for rare conditions or specific combinations of risk factors. Finally, while studies provide context regarding short-term changes in biomarkers, the research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Rosuvastatin Calcium Tablet Label: DailyMed - U.S. National Library of Medicine

Frequently Asked Questions (FAQ)

Common questions about Crestor 5 mg (FAQ)


Q: What is the difference between Crestor and other common statin medicines?

Rosuvastatin, the active ingredient in Crestor, is described in official documents as a synthetic statin. It is recognized as a potent compound, distinguished from some other medicines in its class by its high degree of liver selectivity and a long duration of action.


Q: Does Crestor 5 mg affect both LDL and HDL cholesterol levels?

The official product information indicates that the medicine is designed to lower LDL-C (low-density lipoprotein cholesterol) and total cholesterol. It is also documented to produce modest increases in HDL-C (high-density lipoprotein cholesterol) and is associated with lowering triglycerides.


Q: How long does it typically take for Crestor 5 mg to show its full effect on cholesterol?

Studies cited in regulatory documents indicate that the medicine begins to act within one week, and a response to treatment is usually observed within this time. Approximately 90% of the maximum observed cholesterol-lowering effect is typically reached by two weeks of therapy.


Q: What does the '5 mg' dosage mean in terms of strength or effectiveness?

The 5 mg dose is the lowest available strength in the full dosage range. The 5 mg dose is noted in official guidance as the recommended starting dose for certain patient populations, such as those of Asian descent or individuals with severe kidney impairment. It is typically used for patients who require a moderate level of cholesterol reduction.


Q: Can Crestor 5 mg cause joint pain or muscle stiffness?

The official adverse reaction profile lists myalgia (muscle pain) as a common side effect. Joint pain, often referred to as arthralgia, is generally documented as an uncommon or rare side effect in regulatory documents.


Q: Are there any specific vitamins or supplements known to interact with Crestor 5 mg?

The official interaction profile focuses on prescription medicines, but it does mention co-administration risks with Fibrates and high-dose Niacin. These agents are sometimes used as non-prescription supplements for lipid modification.


Q: What are the main signs of liver problems to watch out for while on this medication?

Official safety information highlights jaundice (yellowing of the skin or eyes) and hepatitis as serious adverse reactions that have been reported. The medicine is contraindicated (not authorized for use) in patients who have active liver disease.


Q: Do people need to avoid grapefruit or grapefruit juice while taking Crestor 5 mg?

According to the official drug documents, rosuvastatin is not listed as having a significant interaction with grapefruit or grapefruit juice that requires avoidance, unlike some other statin medicines. The interaction profile focuses on co-administered medicines and certain antacids.


Q: Does the use of Crestor 5 mg require regular monitoring with blood tests?

Regulatory information notes that Liver Function Tests (LFTs) are recommended to be performed before starting treatment and if the patient develops signs of liver injury. Monitoring for muscle effects, such as checking Creatine Kinase (CK) levels, is also noted for certain high-risk patients.


Q: What is rhabdomyolysis, and what is the risk of it with Crestor 5 mg?

Rhabdomyolysis is a rare adverse reaction that involves the rapid breakdown of damaged muscle tissue. The condition is noted in official documentation due to its potential seriousness and its connection to severe muscle pain.


Q: Can Crestor 5 mg be used by patients with a history of stroke?

Rosuvastatin is indicated for the reduction of Major Adverse Cardiovascular Events (MACE), a category that includes stroke, in patients who have high-risk factors. This indication describes its role in being associated with a reduction in future event frequency for those who have already experienced a primary event.


Q: What age group is Crestor 5 mg commonly prescribed to?

The medicine is indicated for use in adult patients and older adults for the general management of high cholesterol. Its use in children and adolescents (age 7 and up) is typically restricted only to specific genetic conditions, such as Familial Hypercholesterolemia.


Q: Are there long-term effects of taking Crestor 5 mg that users should be aware of?

Studies documented in regulatory sources provide evidence for use over intermediate periods. However, the full extent of very long-term effects are not fully established beyond the median follow-up duration of the major clinical trials.


Q: What happens if a patient stops taking Crestor 5 mg after a long period?

Rosuvastatin is defined in official documents as a long-term, daily medication used to maintain healthy blood lipid profiles. Official guidance implies that if a patient discontinues treatment, the intended cholesterol-lowering effect will cease.


Q: Does Crestor 5 mg interact with common pain relievers like ibuprofen or acetaminophen?

The official interaction profile for rosuvastatin does not list common non-prescription pain relievers like ibuprofen or acetaminophen as having significant drug-to-drug interactions that modify rosuvastatin exposure.


Q: Can Crestor 5 mg cause temporary changes in memory or confusion?

Official documentation notes that post-marketing surveillance reports may include cognitive impairment, such as memory loss or confusion. These events are generally reported as uncommon or rare and have been described as being reversible upon stopping the medicine.


Q: Is it safe to consume alcohol in small amounts while taking Crestor 5 mg?

Official documents do not define a specific limit for alcohol consumption. However, official documents note that caution is advised if a patient consumes substantial quantities of alcohol, due to the potential for increased risk of liver toxicity.


Q: Is Crestor 5 mg appropriate for people with controlled Type 2 diabetes?

Clinical research and labeling documents note that rosuvastatin has been studied and evaluated in high-risk patients, including those with diabetes mellitus, for cardiovascular risk reduction.


Q: Can Crestor 5 mg be used by people with a history of thyroid conditions?

Regulatory information notes that caution is required in patients who have predisposing factors for muscle problems, such as uncontrolled hypothyroidism (an underactive thyroid condition). This is because uncontrolled hypothyroidism can increase the risk of myopathy (muscle disease).


Q: What are the common lifestyle adjustments recommended when starting Crestor 5 mg?

Regulatory documents describe that the medicine is to be used in conjunction with a standard cholesterol-lowering diet. This is the primary lifestyle adjustment specifically noted in the official prescribing information.


Q: Are there any specific food items other than grapefruit that should be avoided?

Official documents do not list any common specific food items that must be strictly avoided. However, the interaction profile does note that a 2-hour spacing for co-administration with aluminum and magnesium antacids is required to mitigate a documented reduction in rosuvastatin absorption.


Q: Does Crestor 5 mg cause or worsen insomnia?

The official adverse reaction profile for rosuvastatin generally does not list insomnia among the frequently reported or uncommon side effects.


Q: Does the effectiveness of Crestor 5 mg change over time?

Rosuvastatin is designed to provide consistent, long-term inhibition of cholesterol synthesis. Official information does not document evidence that the body develops pharmacological tolerance leading to reduced effectiveness over time.

How should Crestor 5 mg be stored and disposed of?

How to Store and Dispose of Crestor 5 mg?

The storage and disposal of Crestor 5 mg (rosuvastatin calcium) tablets must adhere strictly to official regulatory guidelines to maintain product stability and ensure public safety.

Official Storage Requirements

Requirement Specific Condition
Temperature Store at Controlled Room Temperature (20°C to 25°C / 68°F to 77°F).
Container Keep the medicine in its original container with the bottle tightly closed.
Child Safety Must be stored out of the reach and sight of children.

Disposal Instructions

Unused or expired Crestor tablets must be disposed of in accordance with federal and local regulations. Regulatory bodies generally advise against flushing this medication down the toilet to avoid environmental contamination. Patients should follow official instructions regarding drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Crestor 5 mg found in:

A-Z Index: